The antitumor efficacy of Heplipin on S37 sarcoma and B16 melanoma in mice

Purpose:To investigate inhibitory effect of Heplipin on the growth of S37 and B16 implanted into Kunming and C57 mouse respectively. Methods:Heplipin was administrated through gastric inhabatin with the dose of each day such as 3 000 mg/kg (large dose group) 1800 mg/kg(medial dose group) and 1100 mg/kg different (small dose group). Cycolo phosphaincole(CTX, each day 20 mg/kg) and normal saline wasused as postive and negative control respectively. The rates in tumor inhibition, the number of blood vessels, and the rate of necrosis area was tested.Results:The growth suppression of Heplipin to S37 sarcoma and B16 melanoma was 75.1% (large dose, P 0.0001), 69.7% (intermediate dose, P 0.0001), 61.7% (small dose, P 0.01) in Heplipin treated S37 sarcoma laden mice; and 47.0% (large dose, P 0.01), 32.1% (intermediate dose), 13.0% (small dose) in Heplipin treated B16 melanoma laden mice. Histologic examination showed that the number of blood vessels in S37 sarcoma laden mice of large dose group (1.39/field, P 0.01) and intermediate dose group (2.15/field, P 0.05) was less than in that of control groups (6.28/field and 4.70/field ). Heplipin treated groups had more extensive tumor necrosis (75.5% and 60.5%) than the negative control group (48.3%). Conclusions:Heplipin can significantly suppress the growth of the S37 sarcoma and B16 melanoma in mice. The anti tumor mechanism of Heplipin may be related to the inhibition of blood vessel formation resulting in ischemic necrosis of the tumor. [